Inflammation and immune surveillance in cancer

Seminars in Cancer Biology

Volumn 22, Issue 1, 2012, Pages 23-32

  Chow, Melvyn T ^a,b   Möller, Andreas ^a,b   Smyth, Mark J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Danger signal; Immunoediting; Inflammasome; Inflammation; Toll like receptor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CALRETICULIN; CANCER VACCINE; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 1BETA; OXALIPLATIN; TOLL LIKE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EQUILIBRIUM CONSTANT; HOMEOSTASIS; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

CYTOKINES; DISEASE PROGRESSION; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOLOGIC SURVEILLANCE; INFLAMMASOMES; INFLAMMATION; NEOPLASMS; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84857138799     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.12.004     Document Type: Review

References (186)

1. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273-290.
2. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957, 1:841-847.
3. Thomas L. Cellular and humoral aspects of the hypersensitive states 1959, Hoeber-Harper, New York, pp. 529-532.
4. Burstein N., Law L. Neonatal thymectomy and non-viral mammary tumours in mice. Nature 1971, 231:450-452.
5. Grant G., Miller J. Effect of neonatal thymectomy on the induction of sarcomata in C57 BL mice. Nature 1965, 205:1124-1125.
6. Nomoto K., Takeya K. Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice. J Natl Cancer Inst 1969, 42:445-453.
7. Sanford B.H., Kohn H.I., Daly J.J., Soo S.F. Long-term spontaneous tumor incidence in neonatally thymectomized mice. J Immunol 1973, 110:1437-1439.
8. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183:534-536.
9. Dighe A., Richards E., Old L., Schreiber R. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1994, 1:447-456.
10. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci 1998, 95:7556-7561.
11. van den Broek M.E., Kägi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996, 184:1781-1790.
12. Bolitho P., Street S.E.A., Westwood J.A., Edelmann W., MacGregor D., Waring P., et al. Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci 2009, 106:2723-2728.
13. Smyth M.J., Thia K.Y.T., Street S.E.A., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000, 192:755-760.
14. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFN and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
15. Smyth M.J., Thia K.Y.T., Street S.E.A., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000, 191:661-668.
16. Street S., Cretney E., Smyth M. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
17. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001, 294:605-609.
18. Svane I.M., Engel A.M., Nielsen M.B., Ljunggren H.G., Rygaard J., Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996, 26:1844-1850.
19. Engel A.M., Svane I., Rygaard J., Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997, 45:463-470.
20. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
21. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
22. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2009, 28:367-388.
23. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
24. Loeser S., Loser K., Bijker M.S., Rangachari M., van der Burg S.H., Wada T., et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007, 204:879-891.
25. Eyles J., Puaux A-L., Wang X., Toh B., Prakash C., Hong M., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010, 120:2030-2039.
26. Browning M.J., Bodmer W. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992, 4:613-618.
27. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999, 11:68-75.
28. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006, 16:38-52.
29. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16:3-15.
30. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
31. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
32. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
33. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
34. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow. The Lancet 2001, 357:539-545.
35. Swann J.B., Vesely M.D., Silva A., Sharkey J., Akira S., Schreiber R.D., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci 2008, 105:652-656.
36. Teng M.W.L., Andrews D.M., McLaughlin N., von Scheidt B., Ngiow S.F., Möller A., et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci 2010, 107:8328-8333.
37. Krelin Y., Voronov E., Dotan S., Elkabets M., Reich E., Fogel M., et al. Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007, 67:1062-1071.
38. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
39. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
40. Iguchi-Manaka A., Kai H., Yamashita Y., Shibata K., Tahara-Hanaoka S., Honda S-i, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008, 205:2959-2964.
41. Massagué J. TGFβ in cancer. Cell 2008, 134:215-230.
42. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., Fujiki H. Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient Mice. Cancer Res 1999, 59:4516-4518.
43. Cordero J.B., Macagno J.P., Stefanatos R.K., Strathdee K.E., Cagan R.L., Vidal M. Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell 2010, 18:999-1011.
44. Zaidi M.R., Davis S., Noonan F.P., Graff-Cherry C., Hawley T.S., Walker R.L., et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 2011, 469:548-553.
45. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
46. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
47. Mattarollo S.R., Loi S., Duret H., Ma Y., Zitvogel L., Smyth M.J. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011.
48. Agresti A., Bianchi M.E. HMGB proteins and gene expression. Curr Opin Genet Dev 2003, 13:170-178.
49. Park J.S., Arcaroli J., Yum H-K., Yang H., Wang H., Yang K-Y., et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol 2003, 284:C870-C879.
50. DeMarco R.A., Fink M.P., Lotze M.T. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 2005, 42:433-444.
51. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
52. Mitola S., Belleri M., Urbinati C., Coltrini D., Sparatore B., Pedrazzi M., et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006, 176:12-15.
53. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005, 166:1259-1263.
54. Dumitriu I.E., Baruah P., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005, 35:2184-2190.
55. Messmer D., Yang H., Telusma G., Knoll F., Li J., Messmer B., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004, 173:307-313.
56. Kokkola R., Andersson Å., Mullins G., östberg T., Treutiger C.J., Arnold B., et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005, 61:1-9.
57. Park J.S., Svetkauskaite D., He Q., Kim J-Y., Strassheim D., Ishizaka A., et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
58. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
59. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007, 110:1970-1981.
60. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
61. Maeda S., Hikiba Y., Shibata W., Ohmae T., Yanai A., Ogura K., et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007, 360:394-400.
62. Sasahira T., Kirita T., Oue N., Bhawal U.K., Yamamoto K., Fujii K., et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008, 99:1806-1812.
63. Poser I., Golob M., Buettner R., Bosserhoff A.K. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003, 23:2991-2998.
64. Ishiguro H., Nakaigawa N., Miyoshi Y., Fujinami K., Kubota Y., Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64:92-100.
65. Völp K., Brezniceanu M-L., Bösser S., Brabletz T., Kirchner T., Göttel D., et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006, 55:234-242.
66. Takada M., Hirata K., Ajiki T., Suzuki Y., Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004, 51:928-930.
67. Brezniceanu M-L., Völp K., Bösser S., Solbach C., Lichter P., Joos S., et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003, 17:1295-1297.
68. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010, 70:855-858.
69. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358.
70. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci 2010, 107:1547-1552.
71. Stagg J., Divisekera U., Duret H., Sparwasser T., Teng M.W.L., Darcy P.K., et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011, 71:2892-2900.
72. Martins I., Kepp O., Galluzzi L., Senovilla L., Schlemmer F., Adjemian S., et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci 2010, 1209:77-82.
73. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
74. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y-H., et al. A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
75. Michel M-L., Keller A.C., Paget C., Fujio M., Trottein F., Savage P.B., et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med 2007, 204:995-1001.
76. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H.G. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T Cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
77. Coquet J.M., Chakravarti S., Kyparissoudis K., McNab F.W., Pitt L.A., McKenzie B.S., et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci 2008, 105:11287-11292.
78. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
79. Xu S., Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol 2010, 7:164-174.
80. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
81. Benchetrit F., Ciree A., Vives V., Warnier G., Gey A., Sautès-Fridman C.C., et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99:2114-2121.
82. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
83. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., et al. Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011, 208:491-503.
84. Honorati M.C., Neri S., Cattini L., Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006, 14:345-352.
85. Kehlen A., Thiele K., Riemann D., Rainov N., Langner J. Interleukin-17 stimulates the expression of IκBα mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J Neuroimmunol 1999, 101:1-6.
86. Numasaki M., Fukushi J-i Ono M., Narula S.K., Zavodny P.J., Kudo T., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
87. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464.
88. Xiao M., Wang C., Zhang J., Li Z., Zhao X., Qin Z. IFNγ promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 2009, 69:2010-2017.
89. Wu S., Rhee K-J., Albesiano E., Rabizadeh S., Wu X., Yen H-R., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17T cell responses. Nat Med 2009, 15:1016-1022.
90. Ngiow S.F., Smyth M.J., Teng M.W.L. Does IL-17 suppress tumor growth. Blood 2010, 115:2554-2555.
91. Dinarello C.A. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011, 41:1203-1217.
92. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
93. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci 2003, 100:2645-2650.
94. Carmi Y., Rinott G., Dotan S., Elkabets M., Rider P., Voronov E., et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 2011, 186:3462-3471.
95. Elkabets M., Ribeiro V.S.G., Dinarello C.A., Ostrand-Rosenberg S., Di Santo J.P., Apte R.N., et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010, 40:3347-3357.
96. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
97. Nakao S., Kuwano T., Tsutsumi-Miyahara C., Ueda S-i Kimura Y.N., Hamano S., et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth. J Clin Invest 2005, 115:2979-2991.
98. Vasselon T., Detmers P.A. Toll receptors: a central element in innate immune responses. Infect Immun 2002, 70:1033-1041.
99. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008, 8:32-43.
100. Ohashi K., Burkart V., Flohé S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
101. Vabulas R.M., Braedel S., Hilf N., Singh-Jasuja H., Herter S., Ahmad-Nejad P., et al. The endoplasmic reticulum-resident heat shock protein gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002, 277:20847-20853.
102. Liu-Bryan R., Scott P., Sydlaske A., Rose D.M., Terkeltaub R. Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
103. Gondokaryono S.P., Ushio H., Niyonsaba Fo Hara M., Takenaka H., Jayawardana S.T.M., et al. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J Leukoc Biol 2007, 82:657-665.
104. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002, 195:99-111.
105. Scheibner K.A., Lutz M.A., Boodoo S., Fenton M.J., Powell J.D., Horton M.R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006, 177:1272-1281.
106. Karikó K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004, 279:12542-12550.
107. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
108. Hasan U.A., Caux C., Perrot I., Doffin A-C., Menetrier-Caux C., Trinchieri G., et al. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci 2007, 104:8047-8052.
109. Sabroe I., Parker L.C., Dower S.K., Whyte M.K.B. The role of TLR activation in inflammation. J Pathol 2008, 214:126-135.
110. Pasare C., Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364-368.
111. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003, 3:984-993.
112. El-Omar E.M., Ng M.T., Hold G.L. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252.
113. Zheng S.L., Augustsson-Bälter K., Chang B., Hedelin M., Li L., Adami H-O., et al. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk. Cancer Res 2004, 64:2918-2922.
114. Chen Y-C., Giovannucci E., Lazarus R., Kraft P., Ketkar S., Hunter D.J. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005, 65:11771-11778.
115. Hold G.L., Rabkin C.S., Chow W-H., Smith M.G., Gammon M.D., Risch H.A., et al. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
116. Sun J., Wiklund F., Zheng S.L., Chang B., Bälter K., Li L., et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005, 97:525-532.
117. Song C., Chen L.Z., Zhang R.H., Yu X.J., Zeng Y.X. Functional variant in the 3'-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther 2006, 5:1285-1291.
118. Zhou X-X., Jia W-H., Shen G-P., Qin H-d Yu X-J., Chen L-Z., et al. Sequence variants in Toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 2006, 15:862-866.
119. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
120. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
121. Fukata M., Hernandez Y., Conduah D., Cohen J., Chen A., Breglio K., et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 2009, 15:997-1006.
122. Fukata M., Chen A., Vamadevan A.S., Cohen J., Breglio K., Krishnareddy S., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881.
123. Mittal D., Saccheri F., Venereau E., Pusterla T., Bianchi M.E., Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010, 29:2242-2252.
124. Kim S., Takahashi H., Lin W-W., Descargues P., Grivennikov S., Kim Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
125. Yang H-Z., Cui B., Liu H-Z., Mi S., Yan J., Yan H-M., et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS ONE 2009, 4:e6520.
126. Chin A.I., Miyahira A.K., Covarrubias A., Teague J., Guo B., Dempsey P.W., et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I Interferons in tumor immune surveillance. Cancer Res 2010, 70:2595-2603.
127. Harmey J.H., Bucana C.D., Lu W., Byrne A.M., McDonnell S., Lynch C., et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101:415-422.
128. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014.
129. Pries R., Hogrefe L. Induction of c-Myc-dependent cell proliferation through Toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008, 21:209-215.
130. Salaun B., Coste I., Rissoan M-C., Lebecque S.J., Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006, 176:4894-4901.
131. Paone A., Starace D., Galli R., Padula F., De Cesaris P., Filippini A., et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism. Carcinogenesis 2008, 29:1334-1342.
132. Cai Z., Sanchez A., Shi Z., Zhang T., Liu M., Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011, 71:2466-2475.
133. Davis B.K., Wen H., Ting J.P.Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011, 29:707-735.
134. Kaparakis M., Philpott D.J., Ferrero R.L. Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol 2007, 85:495-502.
135. Martinon F., Mayor A., Tschopp The Inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
136. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
137. Guarda G., Zenger M., Yazdi A.S., Schroder K., Ferrero I., Menu P., et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011, 186:2529-2534.
138. Kamp D.W. Asbestos-induced lung diseases: an update. Transl Res 2009, 153:143-152.
139. Maeda M., Nishimura Y., Kumagai N., Hayashi H., Hatayama T., Katoh M., et al. Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 2010, 7:268-278.
140. Otsuki T., Maeda M., Murakami S., Hayashi H., Miura Y., Kusaka M., et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007, 4:261-268.
141. Dostert C., Pétrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
142. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T-D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
143. Allen I.C., TeKippe E.M., Woodford R.M.T., Uronis J.M., Holl E.K., Rogers A.B., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010, 207:1045-1056.
144. Hirota S.A., Ng J., Lueng A., Khajah M., Parhar K., Li Y., et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011, 17:1359-1372.
145. Bauer C., Duewell P., Mayer C., Lehr H.A., Fitzgerald K.A., Dauer M., et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59:1192-1199.
146. Salcedo R., Worschech A., Cardone M., Jones Y., Gyulai Z., Dai R.M., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010, 207:1625-1636.
147. Hu B., Elinav E., Huber S., Booth C.J., Strowig T., Jin C., et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci 2010, 107:21635-21640.
148. van Deventer H.W., Burgents J.E., Wu Q.P., Woodford R-M.T., Brickey W.J., Allen I.C., et al. The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res 2010, 70:10161-10169.
149. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
150. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005, 65:5278-5283.
151. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
152. Bingle L., Lewis C.E., Corke K.P., Reed M.W.R., Brown N.J. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br J Cance. 2005, 94:101-107.
153. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006, 80:705-713.
154. Cui S., Reichner J.S., Mateo R.B., Albina J.E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994, 54:2462-2467.
155. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007, 204:1037-1047.
156. Ghiringhelli Fo Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
157. Conejo-Garcia J.R., Benencia F., Courreges M-C., Kang E., Mohamed-Hadley A., Buckanovich R.J., et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004, 10:950-958.
158. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellm Äìsuppressive activity. Blood 2008, 111:4233-4244.
159. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68:5439-5449.
160. Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β 1. J Immunol 2009, 182:240-249.
161. Nausch N., Galani I.E., Schlecker E., Cerwenka A. Mononuclear myeloid-derived suppressor cells express RAE-1 and activate natural killer cells. Blood 2008, 112:4080-4089.
162. Queen M.M., Ryan R.E., Holzer R.G., Keller-Peck C.R., Jorcyk C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005, 65:8896-8904.
163. Chen Y.L., Wang J.Y., Chen S.H., Yang B.C. Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behaviour. Br J Cancer 2002, 87:359-365.
164. Ebata K., Shimizu Y., Nakayama Y., Minemura M., Murakami J., Kato T., et al. Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model. J Immunol 2006, 176:4113-4124.
165. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-5943.
166. Renukaradhya G.J., Khan M.A., Vieira M., Du W., Gervay-Hague J., Brutkiewicz R.R. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008, 111:5637-5645.
167. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005, 202:1627-1633.
168. Smyth M.J., Crowe N.Y., Pellicci D.G., Kyparissoudis K., Kelly J.M., Takeda K., et al. Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002, 99:1259-1266.
169. Kawano T., Nakayama T., Kamada N., Kaneko Y., Harada M., Ogura N., et al. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 1999, 59:5102-5105.
170. Peng G., Wang H.Y., Peng W., Kiniwa Y., Seo K.H., Wang R-F. Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007, 27:334-348.
171. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., et al. γδ T cells provide an early source of interferon γ in tumor immunity. J Exp Med 2003, 198:433-442.
172. Haabeth O.A.W., Lorvik K.B., Hammarstrom C., Donaldson I.M., Haraldsen G., Bogen B., et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011, 2:240.
173. Huang H., Hao S., Li F., Ye Z., Yang J., Xiang J. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 2007, 120:148-159.
174. Kobayashi M., Kobayashi H., Pollard R.B., Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998, 160:5869-5873.
175. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells. J Exp Med 2003, 197:387-393.
176. Khazaie K., von Boehmer H. The impact of CD4+ CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 2006, 16:124-136.
177. Maloy K.J., Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001, 2:816-822.
178. Erdman S.E., Sohn J.J., Rao V.P., Nambiar P.R., Ge Z., Fox J.G., et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 2005, 65:3998-4004.
179. Kemp R.A., Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001, 167:6497-6502.
180. Olver S., Groves P., Buttigieg K., Morris E.S., Janas M.L., Kelso A., et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res 2006, 66:571-580.
181. Schüler T., Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003, 170:4427-4431.
182. Hong S., Qian J., Yang J., Li H., Kwak L.W., Yi Q. Roles of idiotype-specific T cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 2008, 68:8456-8464.
183. Olkhanud P.B., Damdinsuren B., Bodogai M., Gress R.E., Sen R., Wejksza K., et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 2011, 71:3505-3515.
184. Staquicini F.I., Tandle A., Libutti S.K., Sun J., Zigler M., Bar-Eli M., et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 2008, 68:8419-8428.
185. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., et al. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
186. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010, 184:4006-4016.